Heart disease causes one in four American deaths every year. Edwards Lifesciences, which creates artificial heart valves, including for patients deemed too risky for open surgery, has significantly expanded its international footprint and shows no signs of slowing down. The most promising growth avenue is among lower-risk patients who require noninvasive heart valve replacements.
Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
Company Information
| Overall Score | 1.6 |
| Sector | Health Care |
| Industry | Health Care Equipment and Supplies |
| CEO | Michael Mussallem |
| Website | www.edwards.com |
| HQ Location | Irvine, Calif. |
| Country | U.S. |
| Revenues ($M) (Past 12 Months) | $3,964 |
| Profits ($M) (Past 12 Months) | $725 |
| Market Value as of Oct. 9, 2019 ($M) | $46,754 |
| Employees | 12,800 |